NovaVive Inc. - Canine, 15 Dairy Avenue, Napanee, ON (2026)

01/08/2026

Cancer is the leading cause of death in senior dogs in North America. The Animal Cancer Foundation in the U.S. estimates that approximately 6 million dogs are diagnosed with cancer in the U.S. alone each year. About 40% of these will die from the disease annually.

Immunocidin® is our regulator-approved anticancer immunotherapy for the treatment of canine mammary tumors and mammary adenocarcinoma. It is approved and available in the U.S. and Canada.

NovaVive has an ongoing program exploring other cancers for which Immunocidin may be effective. Veterinarians who are interested in exploring Immunocidin as a treatment option are in regular contact with the NovaVive technical team to consider the best approaches. Each case is unique and responds differently to therapy.

For more information, visit NovaVive.ca/products.

12/24/2025

NovaVive extends the very best of the season to you and your loved ones … and wishes you a happy, healthy, and successful new year.

See you in 2026!

12/18/2025

Tank sadly lost his battle with cancer. However, we were glad to be able to offer support for more than three years with Immunocidin therapy.

Immunocidin immunotherapy is regulator-approved in the USA and Canada for the treatment of canine mammary cancer, but it is being used experimentally to treat a variety of other cancer types, including osteosarcoma.

Immunocidin has also proven helpful as a palliative (end-of-life) support for dogs when treatment is no longer an option.

Learn more at NovaVive.ca/products or ask your veterinarian to contact us.

12/11/2025

Immunocidin® immunotherapy has proven safe and effective as an intratumoral treatment for canine mammary cancer. Further research has demonstrated that it can also be safely administered by IV injection.

Immunocidin is approved by regulators in the USA and Canada. Research is ongoing with this product in various tumor types using different administration methods.

Visit NovaVive.ca/products for more information.

12/04/2025

Seeing our beloved pets reach the end of their lives is difficult. Often, there are no further treatment options and we must face losing them.

Immunocidin immunotherapy has been used as a palliative treatment to help pets stay comfortable. Ask your veterinarian about Immunocidin or visit NovaVive.ca/products for more information.

11/27/2025

Immunocidin immunotherapy is approved by regulators in the USA and Canada for the treatment of canine mammary cancer.

NovaVive continues to explore other cancers for which Immunocidin may be effective. One of these is osteosarcoma (bone cancer).

Learn more about Immunocidin research at http://novavive.ca/canine-research.

11/20/2025

NovaVive is pleased to help Pickles live his best life despite a cancer diagnosis.

More than two years after his diagnosis, Pickles is continuing to have adventures with his family. Immunocidin immunotherapy has facilitated this.

The product is approved by regulators in the USA and Canada for the treatment of canine mammary cancer, but the Company continues to explore other cancers for which Immunocidin may be effective. One of these is osteosarcoma.

Ask your veterinarian about this product or learn more about Immunocidin research at http://novavive.ca/canine-research.

11/13/2025

Immunocidin® immunotherapy works by stimulating direct and indirect anticancer activity in the dog. Our technology helps make a tumor recognizable to the animal’s immune system.

The product is approved in the USA and Canada for treating canine mammary cancer and research is ongoing in other tumor types.

Visit NovaVive.ca/products to learn more

11/06/2025

Immunocidin® immunotherapy is approved in the USA and Canada for the treatment of canine mammary cancer, but it is being used experimentally to treat a variety of other cancer types.

Immunocidin has also proven helpful as a palliative (end-of-life) support for dogs when treatment is no longer an option.

It is safe to use in all veterinary clinics.

Learn more at NovaVive.ca/products or ask your veterinarian to contact us.

10/30/2025

Immunocidin® immunotherapy has proven safe and effective as an intratumoral treatment for canine mammary cancer. Further research has demonstrated that it can also be safely administered by IV injection.

Immunocidin is approved by regulators in the USA and Canada. Research is ongoing with this product in various tumor types using different administration methods.

Visit NovaVive.ca/products for more information.

10/23/2025

NovaVive is pleased to help Sophie live her best life despite a cancer diagnosis.

Four years after her diagnosis, Sophie is continuing to delight her family. Three months of Immunocidin immunotherapy contributed to this outcome.

This product is approved by regulators in the USA and Canada for the treatment of canine mammary cancer, but the Company continues to explore other cancers for which Immunocidin may be effective. One of these is bladder cancer.

Learn more about Immunocidin research at http://novavive.ca/canine-research.

NovaVive Inc. - Canine

01/08/2026

12/24/2025

12/18/2025

12/11/2025

12/04/2025

11/27/2025

11/20/2025

11/13/2025

11/06/2025

10/30/2025

10/23/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share